10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Valproic acid increases SMN levels in spinal muscular atrophy patient cells.

      Annals of Neurology
      Anticonvulsants, pharmacology, Cell Line, Child, Preschool, Cyclic AMP Response Element-Binding Protein, Dose-Response Relationship, Drug, Fibroblasts, drug effects, physiology, Humans, Immunoblotting, Immunohistochemistry, Infant, Infant, Newborn, Nerve Tissue Proteins, biosynthesis, Promoter Regions, Genetic, RNA-Binding Proteins, Reverse Transcriptase Polymerase Chain Reaction, SMN Complex Proteins, Spinal Muscular Atrophies of Childhood, genetics, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein, Time Factors, Transcription, Genetic, Valproic Acid

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused by mutation of the telomeric copy of the survival motor neuron gene (SMN1). Although a centromeric copy of the survival motor neuron gene (SMN2) is retained in all patients with SMA, it differs from SMN1 at a critical nucleotide such that the majority of SMN2 transcripts lack exon 7 and encode an unstable, truncated protein. Here, we show that valproic acid increases levels of exon 7-containing SMN transcript and SMN protein in type I SMA patient-derived fibroblast cell lines. Valproic acid may increase SMN levels both by activating the SMN promoter and by preventing exon 7 skipping in SMN transcripts. Valproic acid and related compounds warrant further investigation as potential treatment for SMA.

          Related collections

          Author and article information

          Comments

          Comment on this article